Published in J Natl Cancer Inst on July 01, 1972
BCG immunotherapy of a rat sarcoma. Br J Cancer (1973) 1.50
Immunotherapy of Cancer with Nonliving BCG and Fractions Derived from Mycobacteria: Role of Cord Factor (Trehalose-6, 6'-Dimycolate) in Tumor Regression. Infect Immun (1974) 1.31
Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin Exp Immunol (2003) 1.12
Subversion of host defense mechanisms by malignant tumors: an established tumor as a privileged site for bacterial growth. J Exp Med (1977) 0.97
Stimulation of lymphocyte proliferation by killed mycobacteria and other bacterial species. Infect Immun (1976) 0.87
Antitumor activity of Listeria monocytogenes on a guinea pig fibrosarcoma. Infect Immun (1979) 0.85
Non-specific immunotherapy with bacille Calmette-Guérin (BCG). Clin Exp Immunol (2001) 0.84
Modulation of the immune response by BCG: a review. Yale J Biol Med (1976) 0.82
Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review. Int Braz J Urol (2009) 0.80
Corynebacterium parvum stimulation of adherent and non-adherent cytotoxic cells in mice. Br J Cancer (1981) 0.78
The relationship of immune status to the efficacy of immunotherapy in preventing tumour recurrence in mice. Br J Cancer (1974) 0.78
Update on intravesical agents for non-muscle-invasive bladder cancer. Immunotherapy (2010) 0.76
[Intratumor immunotherapy with BCG cell wall preparations: development of a new therapy approach for head-neck tumors]. Arch Otorhinolaryngol (1982) 0.76
Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease. Bladder Cancer (2015) 0.76
Adjuvant BCG immunotherapy for malignant melanoma. Can Med Assoc J (1984) 0.76
Tumor regression at an untreated site during immunotherapy of an identical distant tumor. Proc Natl Acad Sci U S A (1975) 0.75
Influence of orally administered B.C.G. on growth of transplanted rat tumours. Br J Cancer (1975) 0.75
Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice. Am J Pathol (1976) 0.75
Regression by active specific immunotherapy of established dermal tumor transplants and lymph node metastases in guinea pigs. Infect Immun (1981) 0.75
Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder. The Finnbladder Research Group. World J Urol (1997) 0.75
Intravesical BCG induces CD4(+) T-Cell Expansion in an Immune Competent Model of Bladder Cancer. Cancer Immunol Res (2017) 0.75
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement. J Immunol (1967) 8.06
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med (2000) 4.55
Complement fixation on cell surfaces by 19S and 7S antibodies. Science (1965) 4.04
Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med (1999) 3.76
Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res (1994) 3.62
Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature (1987) 3.46
Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte. J Immunol (1965) 3.42
Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. Lancet (2001) 3.39
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. Arch Dermatol (1999) 3.14
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A (1997) 2.92
Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology (2008) 2.87
Complement and Hemolysis. Science (1963) 2.73
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet (2001) 2.68
Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata. Nature (1985) 2.67
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat (1998) 2.64
Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci (2000) 2.57
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood (2001) 2.53
Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest (1988) 2.53
Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet (1994) 2.52
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet (1998) 2.50
Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol (1993) 2.50
Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA (1995) 2.43
von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology (1995) 2.38
A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene (2000) 2.35
Autogenous immunity to endogenous RNA tumor virus. Radioimmune precipitation assay of mouse serum antibody levels. J Exp Med (1973) 2.31
Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood (1986) 2.27
Localization of 125I-labeled antigen in germinal centers of mouse spleen: histologic and ultrastructural autoradiographic studies of the secondary immune reaction. J Immunol (1968) 2.21
The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain (2005) 2.17
BCG and cancer (first of two parts). N Engl J Med (1974) 2.13
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
Autogenous immunity to endogenous RNA tumor virus. Identification of antibody reactivity to select viral antigens. J Exp Med (1974) 2.10
Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cell Immunol (1974) 2.07
The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells. Blood (1998) 2.05
Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med (1989) 2.05
Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst (1971) 2.04
Neurological channelopathies. Postgrad Med J (2005) 1.98
Forssman antigen and antibody: preparation of water soluble antigen and measurement of antibody concentration by precipitin analysis, by C'1a fixation and by hemolytic activity. J Immunol (1966) 1.95
Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res (1995) 1.91
Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain (2007) 1.91
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 1.90
The ultrastructure of antigen localization and viruslike particles in mouse spleen germinal centers. Exp Mol Pathol (1968) 1.86
Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet (2005) 1.85
A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy. Brain (1999) 1.84
Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst (1974) 1.82
Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene (1995) 1.82
The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A (2001) 1.81
Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science (1971) 1.80
Electron microscopic autoradiography of germinal center cells in mouse spleen. J Cell Biol (1965) 1.78
Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guérin strain of Mycobacterium bovis. J Natl Cancer Inst (1972) 1.75
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res (1999) 1.74
Tumor cytotoxicity in vitro by macrophages from mice infected with mycobacterium bovis strain BCG. J Natl Cancer Inst (1974) 1.74
A human homologue of the Drosophila developmental gene, Notch, is expressed in CD34+ hematopoietic precursors. Blood (1994) 1.74
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) (2003) 1.71
BCG and cancer. N Engl J Med (1974) 1.66
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res (1998) 1.66
The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain (2009) 1.65
Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol (2000) 1.64
Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am (2006) 1.64
Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood (1991) 1.64
Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG). Science (1970) 1.64
Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA (1997) 1.63
Neutralization of sensitized virus by purified components of complement. Proc Natl Acad Sci U S A (1970) 1.63
Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. 3. The hemolytic efficiency of human and guinea pig C2 and C4. J Immunol (1971) 1.60
Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins. Neurology (2010) 1.59
Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell Biol (2001) 1.58
Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci U S A (1992) 1.56
Tumor regression after intralesional injection of emulsified trehalose-6,6'-dimycolate (cord factor): efficacy increases with oil concentration. Int J Cancer (1977) 1.56
Inhibition of granulocytic differentiation by mNotch1. Proc Natl Acad Sci U S A (1996) 1.54
Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res (1992) 1.52
Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol (1999) 1.52
Polypeptides of mammalian oncornaviruses. III. Localization of p 15 and reactivity with natural antibody. Virology (1975) 1.48
Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. I. Tumor growth and metastasis. J Natl Cancer Inst (1972) 1.47
Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res (1998) 1.46
Tumor-specific antigen solubilized by hypertonic potassium chloride. J Natl Cancer Inst (1971) 1.46
Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry (2009) 1.46
Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group. J Clin Oncol (1994) 1.45
Synthesis of the first component of human complement in vitro. J Exp Med (1968) 1.44